SalioGen Therapeutics Funding: $135M Raised, Series B (2022)
SalioGen Therapeutics is based in Boston. It has raised $135M in total funding. Latest round: Series B.
SalioGen Therapeutics funding overview
SalioGen Therapeutics is based in Boston. SalioGen Therapeutics has raised $135M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in January 2022. The round record for SalioGen Therapeutics runs through 2022; nothing later has been disclosed. Investors on record include GordonMD Global Investments, EPIQ Capital Group, PBM Capital, Cystic Fibrosis Foundation, Foundation for Fighting Blindness, D1 Capital Partners and 4 others. 10 distinct backers are named across the disclosed rounds.
SalioGen Therapeutics at a glance
Total raised
$135M
Latest round
Series B
Latest round date
January 2022
Headquarters
Boston
Notable investors
GordonMD Global Investments, EPIQ Capital Group, PBM Capital, Cystic Fibrosis Foundation, Foundation for Fighting Blindness, D1 Capital Partners, Fidelity Management & Research Company, T. Rowe Price Associates
Frequently asked about SalioGen Therapeutics funding
How much has SalioGen Therapeutics raised?
SalioGen Therapeutics has raised $135M in total disclosed funding across the rounds on record.
Who has invested in SalioGen Therapeutics?
GordonMD Global Investments, EPIQ Capital Group, PBM Capital, Cystic Fibrosis Foundation, Foundation for Fighting Blindness, D1 Capital Partners are named among the investors backing SalioGen Therapeutics.
What was the latest SalioGen Therapeutics funding round?
The most recent disclosed round is a Series B, announced in January 2022.
Where is SalioGen Therapeutics based?
SalioGen Therapeutics is based in Boston.
When did SalioGen Therapeutics last raise?
The last disclosed SalioGen Therapeutics round closed in January 2022 at Series B.
Totals shown for SalioGen Therapeutics aggregate every disclosed round on file. To see how that compares, browse the companies in Boston and the investors behind them below.
